Medtronic did not comment on the subpoena, but previously disclosed that it paid approximately $800,000 to Dr. Kuklo in consulting fees, the majority of which was given to him during the time he performed the Infuse study.
The study, which appeared in the British edition of the The Journal of Bone and Joint Surgery, found that Infuse performed significantly better at repairing leg injuries suffered by American combat soldiers in Iraq than a traditional bone graft. The study was recently challenged, and Dr. Kuklo has been accused of falsifying data.
Read the New York Times’ report on the Medtronic subpoena.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
